Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI
    • نبذة مختصرة :
      Commercially available anti-CD19 chimeric antigen receptor T cells (CARΤ cells) have offered long-term survival to a constantly expanding patient population. Given that novel toxicities including cytokine release syndrome (CRS) and neurotoxicity (ICANS) have been observed, we aimed to document the safety and toxicity of this treatment in a real-world study. We enrolled 31 adult patients referred to our center for CAR T therapy. Tisagenlecleucel was infused in 12 patients, axicabtagene ciloleucel in 14, and brexucabtagene autoleucel in 5. Cytokine release syndrome was noted in 26 patients while neurotoxicity was observed in 7. Tocilizumab was administered for CRS in 18 patients, along with short-term, low-dose steroid administration in one patient who developed grade III CRS and, subsequently, grade I ICANS. High-dose steroids, along with anakinra and siltuximab, were administered in only two MCL patients. With a median follow-up time of 13.4 months, nine patients were then in CR. The progression-free (PFS) and overall survival (OS) rates were 41.2% and 88.1% at one year, respectively. MCL diagnosis, which coincides with the administration of brexucabtagene autoleucel, was the only factor to be independently associated with poor OS ( p < 0.001); meanwhile, increased LDH independently predicted PFS ( p = 0.027).In addition, CRP at day 14 was associated with a poor OS ( p = 0.001). Therefore, our real-world experience confirmed that commercial CAR T therapy can be administered with minimal toxicity.
    • References:
      Clin Cancer Res. 2022 May 2;28(9):1759-1764. (PMID: 35046063)
      Cell. 2020 Oct 1;183(1):126-142.e17. (PMID: 32961131)
      Blood. 2015 Mar 5;125(10):1548-52. (PMID: 25573993)
      Nat Rev Clin Oncol. 2018 Jan;15(1):31-46. (PMID: 28857075)
      Lancet Oncol. 2019 Jan;20(1):31-42. (PMID: 30518502)
      Blood. 2017 Nov 23;130(21):2295-2306. (PMID: 28924019)
      Blood. 2021 Dec 16;138(24):2469-2484. (PMID: 34525183)
      Blood. 2015 May 7;125(19):2908-14. (PMID: 25758828)
      Clin Cancer Res. 2022 Sep 1;28(17):3804-3813. (PMID: 35705524)
      Cancer Discov. 2016 Jun;6(6):664-79. (PMID: 27076371)
      Blood. 2020 Apr 16;135(16):1332-1343. (PMID: 32107531)
      Blood. 2019 Jun 6;133(23):2465-2477. (PMID: 30992265)
      Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. (PMID: 30592986)
      Cancer Discov. 2017 Dec;7(12):1404-1419. (PMID: 29025771)
      N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
      N Engl J Med. 2020 Apr 2;382(14):1331-1342. (PMID: 32242358)
      CNS Drugs. 2018 Dec;32(12):1091-1101. (PMID: 30387077)
      N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
      Lancet. 2021 Jul 24;398(10297):314-324. (PMID: 34175021)
      Bone Marrow Transplant. 2021 Mar;56(3):552-566. (PMID: 33230186)
      Sci Transl Med. 2014 Feb 19;6(224):224ra25. (PMID: 24553386)
      Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. (PMID: 30190371)
      Lancet. 2015 Feb 7;385(9967):517-528. (PMID: 25319501)
      Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. (PMID: 36906275)
      Nat Med. 2018 Jun;24(6):731-738. (PMID: 29808005)
      Blood Adv. 2022 Jun 28;6(12):3606-3610. (PMID: 35271707)
      Am J Hematol. 2021 Aug 1;96(8):E298-E301. (PMID: 33984157)
      Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694. (PMID: 30965140)
      J Rheumatol. 2021 Oct;48(10):1596-1602. (PMID: 33589555)
      Cancer Gene Ther. 2015 Mar;22(2):79-84. (PMID: 25675873)
      Lancet. 2007 Oct 20;370(9596):1453-7. (PMID: 18064739)
      J Allergy Clin Immunol. 2020 Nov;146(5):940-948. (PMID: 32771558)
      Nat Rev Cancer. 2021 Mar;21(3):145-161. (PMID: 33483715)
      Int J Mol Sci. 2020 May 29;21(11):. (PMID: 32485958)
      Br J Haematol. 2021 Aug;194(4):701-707. (PMID: 34263927)
      Front Immunol. 2020 Dec 16;11:577027. (PMID: 33391257)
      N Engl J Med. 2017 Dec 28;377(26):2545-2554. (PMID: 29226764)
      N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490)
      Transplant Cell Ther. 2023 Jul;29(7):430-437. (PMID: 37031746)
      J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):269-272. (PMID: 32850076)
      Blood Adv. 2019 Jul 23;3(14):2230-2236. (PMID: 31332046)
      Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. (PMID: 28925994)
      Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. (PMID: 31187533)
      Ann Neurol. 2019 Jul;86(1):42-54. (PMID: 31074527)
      Blood. 2021 Jun 10;137(23):3272-3276. (PMID: 33534891)
      Cancer Discov. 2018 Aug;8(8):958-971. (PMID: 29880584)
      Blood. 2016 Jun 30;127(26):3321-30. (PMID: 27207799)
      Lancet Oncol. 2021 Oct;22(10):1403-1415. (PMID: 34516954)
      Blood Adv. 2020 Nov 10;4(21):5414-5424. (PMID: 33147337)
      Nat Med. 2018 Jun;24(6):739-748. (PMID: 29808007)
    • Contributed Indexing:
      Keywords: CAR T cells; axicabtagene ciloleucel; brexucabtagene autoleucel; cytokine release syndrome (CRS); immune-effector-cell-associated neurotoxicity syndrome (ICANS); tisagenlecleucel; toxicity
    • الموضوع:
      Date Created: 20230909 Latest Revision: 20230911
    • الموضوع:
      20230911
    • الرقم المعرف:
      PMC10487155
    • الرقم المعرف:
      10.3390/cancers15174253
    • الرقم المعرف:
      37686529